On 13 July 2026, the UK and Switzerland announced the conclusion of negotiations for an enhanced Free Trade Agreement (“FTA”) (see here and here). At the time of writing, the final treaty text has not yet been published, and the analysis below is based on the information released by the UK and Swiss Governments announcing the conclusion of negotiations. While the agreement covers a broad range of trade and economic issues and much of the…
Tariffs and shifting trade dynamics continue to disrupt healthcare and life sciences supply chains. But in addition to affecting operational and commercial outlooks for business, they are also revealing new opportunities for innovators and investors. In the final article of the series, we explore five key questions:
As supply chains shift and vendor arrangements evolve in response to tariffs, life sciences companies must adapt to increasingly intricate and intertwined challenges across operational and commercial needs. Manufacturing relocation, technology adoption, and new vendor partnerships require careful oversight of labor, compliance, human rights, and union matters. Protecting IP and data is vital against brand, legal, and cyber risks. Early IP registration, strong contracts, audits, and compliance help manage regulations and reduce Anti-Money Laundering (AML)…
